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abundance and accessibility of specific targetable molecules 
and selection of patients who may benefit from the addition 
of targeted agents to radiotherapy. In the nearby future, the 
combination of tracers with a long and a short half-life may 
facilitate simultaneous imaging of different tumour 
characteristics. Furthermore, the introduction of integrated 
PET-MRI imaging will most likely provide a combination of 
superior anatomical and functional information. 
Small studies employing adaptive radiotherapy based on 
functional dynamics and early response mechanisms 
demonstrate promising results. However, each PET tracer has 
demonstrated its potential as well as pitfalls regarding 
application in everyday clinical practice. Further validation in 
multicenter set-up is needed. Immunohistochemistry and 
gene arrays may help to select which therapeutic pathway is 
most suitable for an individual tumour and, therefore, which 
type of molecular PET imaging will be relevant. Ultimately, 
this should result in availability for routine clinical practice 
requiring stable production and accessibility of tracers, 
reproducibility and standardization of imaging and analysis 
methods, as well as general availability of knowledge and 
expertise. 
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Clinical trials are an excellent tool for evaluating the 
effectiveness of a single change in patient management on 
later outcomes.  In the rapidly evolving landscape of clinical 
practice, a plethora of incremental changes may either exert 
a background effect, or be introduced during the conduct of 
a clinical trial.  These can have the effect of blunting, or 
even overwhelming, the impact of the intervention being 
assessed in a randomized study.  Using various examples from 
recently reported clinical trials investigating radiation dose 
escalation, we explore this phenomenon, and speculate on 
how future research may be able to adapt accordingly.  
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Purpose/Objective: Multimodal imaging has the potential to 
increase the accuracy of head and neck squamous cell 
carcinoma target volume delineation. This study aims to 
quantify the variation in Oropharyngeal Squamous Cell 
Carcinoma (OSCC) Gross Tumour Volume (GTV) delineation 
between CT, MR and 18FDG-PET imaging. 
Materials and Methods: A prospective, single centre, pilot 
study was undertaken where 11 patients with locally 
advanced OSCC (2 tonsil, 9 base of tongue primaries) 
underwent pre-treatment, contrast enhanced, 18FDG-PET-CT, 
and T1- and T2-weighted MR imaging, all performed in a 
radiotherapy treatment mask. GTVs were contoured by 6 
clinicians (2 radiologists and 4 radiation oncologists) using CT 
and MRI (T1 and T2 sequences) independently and co-
registered CT and MRI (rigidly co-registered using Mirada RTx 
v1.4, Mirada Medical, Oxford, UK). Clinical information and 
available diagnostic imaging was on hand during contouring. 
A 2 week gap was imposed between individual patient 
delineations to minimise recollection. The semi-automatic 
Schaefer adaptive algorithm contoured the 18FDG-PET GTVs. 
Volume and positional metrics assessed the GTV variation 
with imaging modality. Linear mixed effects models were 
used to determine GTV volume variations, accounting for 
inter-patient and inter-operator variability. Six delineation 
error metrics (described in table 1, ImSimQA, v3.1.5, OSL, 
Shrewsbury, UK) were used to determine the inter-observer 
variability in GTV position within modalities and the variation 
in GTV position between modalities. 
Results: Volumes: The mean GTV volumes were: CT 11.9cm3 
(SD = 4.5cm3); CT-MR 14.1cm3 (SD = 3.7cm3); MR 12.7 cm3 (SD 
= 2.5cm3); and 18FDG-PET 9.5cm3 (SD = 6.8cm3). Significant 
GTV volume differences were found between CT and CT-MR ( 
p < 0.0005), CT-MR and 18FDG-PET ( p < 0.0009) and MR and 
18FDG-PET ( p < 0.016) modalities. MR had a significantly 
smaller inter-operator variability ( p < 0.05) compared to CT. 
Figure 1 shows the GTV volumes for all patients for all 
modalities. 
Positional metrics: The CT inter-observer variability was 
found to be significantly higher ( p <0.05) than both MR and 
CT-MR modalities for all positional metrics except for the 
mean distance to conformity (Table 1). Differences in GTV 
position were found between all modalities with the 
exception of the positionally similar CT-MR and MR GTVs 
(Table 1). 
 
 
Conclusions: Inter-observer variation using MRI for GTV 
delineation was significantly less than when using CT. The 
use of different imaging modalities (CT, MR and 18FDG-PET) 
produced significantly different GTVs which varied in volume 
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or position, with no single imaging modality encompassing all 
potential GTV regions. These data suggest delineation based 
upon multimodality imaging has the potential to improve the 
accuracy of GTV definition, which is important for highly 
volumetric approaches to target volume delineation and dose 
escalation strategies.  
   
OC-0064   
Hypercellularity components of glioblastoma identified by 
high b-value DWI: the potential for target definition 
P.P. Pramanik1, H.A. Parmar2, A.G. Mammoser3, L.R. Junck3, 
M.M. Kim1, C.I. Tsien1, T.S. Lawrence1, Y. Cao4 
1University of Michigan, Radiation Oncology, Ann Arbor, USA  
2University of Michigan, Radiology, Ann Arbor, USA  
3University of Michigan, Neurology, Ann Arbor, USA  
4University of Michigan, Radiation Oncology-Radiology-
Biomedical Engineering, Ann Arbor, USA  
 
Purpose/Objective: Conventional MRI for target definition of 
glioblastoma (GB) may receive inadequate radiation dose 
coverage of the nonenhanced (NE) hypercellular (HC) 
subvolume resulting in reduced therapeutic efficacy. It is a 
challenge to differentiate NE solid tumor from edema using 
conventional FLAIR and ADC (b≤1000 s/mm2) images. This 
study aimed to develop a technique to identify the HC 
components of GB by using high b-value diffusion weighted 
imaging (DWI) and to investigate the relationship of these 
components with the enhanced subvolumes, 95% prescribed 
radiation dose volume (95PDV) and progression-free survival 
(PFS). 
Materials and Methods: 21 patients (age: 23-76 years) with 
GB were treated by radiation therapy (RT) after surgical 
resection or biopsy. RT planning was based upon conventional 
MRI. During MRI simulation, DWI was acquired in 3 orthogonal 
directions with b-values of 0, 1000, and 3000 s/mm2. Gross 
tumor volume (GTV-Gd) and FLAIR abnormality volume (FLAIR 
TV) were defined on post-Gadolinium T1-weighted and T2 
FLAIR images pre-RT. High b-value (3000 s/mm2) DWI, in 
which fluid, edema, grey and white matter, to an extent, are 
suppressed, were used to define the HC volume (HCV) by 
using a threshold (mean intensity + 2 SD) calculated from a 
VOI in normal-appearing tissue most contralateral to the 
tumor (Fig 1). All images, including planning CT (dose 
distribution) and MRI at recurrence, were registered to post-
Gd T1WI pre-RT. Relationships between the HCV, GTV-Gd, 
FLAIR TV, 95PDV and PFS were analyzed. 
 
 
 
Results: The HCVs and NE HCVs varied from 0.58 to 67 cc 
(median: 9.8 cc) and 0.15 to 60 cc (median: 2.5 cc), 
respectively. 14 patients had incomplete dose coverage of 
the HCV, of which 6 patients had 1 cc or more HCV missed by 
the 95PDV (range: 1.01-25.4 cc), indicating insufficient 
radiation dose coverage of the HCVs when using conventional 
MRI. In 7 patients, HCVs extended beyond FLAIR TVs an 
average of 13 mm (range: 5-27 mm). However, overall, HCVs 
were only a median 12% of the FLAIR TVs (median volume of 
70 cc and range: 23-180 cc), indicating a potential risk of 
radiation toxicity if FLAIR TV is used to guide high-dose 
treatment. Of the 15 patients who had progression, 5 
patients progressed earlier, within 6 months post-RT, and 10 
patients after. Pre-RT HCVs within the recurrent GTVs-Gd 
were 78% (range: 65-89%) for the earlier progression subgroup 
and 53% (range: 0-85%) for the later progression subgroup, 
indicating the consequence of HCV on PFS. In fact, HCV and 
NE HCV were significant negative prognostic indicators for 
PFS (univariate cox regression, n = 21, p < 0.002 and p < 0.01, 
respectively). The volume of HCV that was not covered by 
the 95PDV was also a significant negative predictor for PFS (p 
< 0.05), substantiating the importance of high dose coverage 
of the HCV.  
Conclusions: High b-value DWI identifies the HC components 
of GB and could aid in RT target volume definition. Future 
pathological studies will allow us to investigate the role of 
high b-value DWI in identifying radiation boost volumes and 
diagnosing progression. 
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Purpose/Objective: Hyperthermia treatment (HT) aims at 
tumour heating to approximately 43°C using RF antennas for 
energy deposition. For accurate Hyperthermia Treatment 
Planning (HTP), the knowledge of patient-specific electrical 
tissue conductivity (σ) values is required. Currently, HTP 
applies literature values for σ, which show large variations 
due to variable measuring conditions (e.g. in vivo, ex vivo, 
temperature) and use of various species. As σ has a strong 
impact on the Specific Absorption Rate (SAR) and 
temperature distribution, studies have shown that 
uncertainties in tissue σ can lead to inaccuracies of 20% in 
both SAR and temperature predictions for HTP. Therefore, 
accurate σ values are essential for reliable patient-specific 
HTP. Moreover, tumor σ is unknown; therefore currently σ 
values of muscle are applied. Our aim is to acquire patient-
specific tissue σ non-invasively using MRI. 
Materials and Methods: In vivo σ reconstructions were 
performed using the Electric Property Tomography (EPT) 
method which reconstructs the tissue σ from the B1+ fields, as 
measurable by standard MRI systems. We have validated this 
method earlier using phantom experiments and in vivo 
simulations in the pelvic region. In the present study, in vivo 
3T MRI measurements of 12 cervical (squamous cell) 
carcinoma patients and one uterine adenocarcinoma patient 
were used to reconstruct σ values in tumor, muscle and 
bladder. For a reliable σ reconstruction using EPT, the size of 
a particular tissue type should be relatively homogenous and 
large enough (>3cm), therefore, the σ of 9 tumors and 7 
bladder fillings could be reliably reconstructed. Results were 
compared to literature data. 
